Utah Medical Products, Inc. (UTMD)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$69.72+0.81%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Broken: Primary pillar broken — Maintain consistent revenue aligned with projections: Q2 FY26 revenue $8.53M vs $8.72M target.
Utah Medical Products keeps steady sales with $8.72M revenue in Q1 2026. The company expects to earn about $0.82 per share in 2026. It has a moderate risk profile and trades cheaper than peers. Dividend increases show stable cash flow.
Revenue is expected to shrink about 3% next year. The company has mixed progress on its goals. No clear growth drivers are visible. Competition and market pressures could hurt margins and sales.
The market expects about a 3% decline in revenue next year and prices the stock slightly below our valuation. Our view aligns with this cautious outlook but sees potential if the company meets its earnings target.
Breaks if: EPS falls below $0.82 in FY26
Deliver financial results consistent with previously announced projections for calendar year 2026.
Newly stated in 2026-Q1. Management reported 1Q 2026 financial results consistent with projections despite a 10.2% revenue decline compared to 1Q 2025. EPS declined 11.0% but was in line with expectations. The trajectory matches management's stated consistency with projections.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable company facing revenue decline but with a solid management team. The current thesis is intact, supported by strong recent financial performance despite ongoing challenges.
The market appears to have priced in a neutral valuation, with expectations that are slightly below peers. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news.
Fundamentals may continue to show mixed results as management works to recover lost sales and control litigation costs. Recent financial performance has been strong, but ongoing revenue declines could pose risks.
The thesis hinges on management's ability to manage revenue decline and recover sales, as well as external factors like sector performance and macroeconomic conditions. Positive signals from larger healthcare companies could support UTMD's performance.
The most important moves since the prior daily snapshot.
Valuation rose by 10.3 points (from 50.8 to 61.1).
Signal changed from 'mild_favorable' to 'favorable'.
Yes, our read has weakened. Declining revenue is a cause for concern. This impacts management's goal to recover lost sales. The market is also facing a risk-off environment.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“In 1Q 2026, Utah Medical Products attained financial results consistent with previously announced projections for 2026.”
Breaks if: Any OEM sales to PendoTech or blood pressure kits shipped to China in 2026
Breaks if: Quarterly revenue falls below $8.72M in any quarter
Deliver financial results consistent with previously announced projections for calendar year 2026.
Newly stated in 2026-Q1. Management reported 1Q 2026 financial results consistent with projections despite a 10.2% revenue decline compared to 1Q 2025. EPS declined 11.0% but was in line with expectations. The trajectory matches management's stated consistency with projections.
“In 1Q 2026, Utah Medical Products attained financial results consistent with previously announced projections for 2026.”
In the next 1 to 3 years, UTMD's performance will depend on its management execution and sector trends. Not investment advice.